Prometheus Biosciences Stock (US7401921006): quiet post-takeover listing keeps RXDX in focus

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 12, 2026 at 2:55 PM ET. Details in the imprint.

Prometheus Biosciences, best known to many investors under its former Nasdaq ticker RXDX, no longer trades as a standalone stock after being acquired by Merck several years ago, but the legacy ISIN US7401921006 still appears in some portfolio and data systems and keeps the name on watchlists. In May 2023, Merck announced the completion of its all-cash acquisition of Prometheus Biosciences for $200.00 per share, valuing the inflammatory-disease focused biotech at roughly $10.8 billion and removing RXDX from the Nasdaq Global Select Market. Since closing of the deal, public trading in Prometheus shares ceased, and Merck has fully integrated the company’s precision immunology pipeline, including the ulcerative colitis and Crohn’s disease candidate PRA023 (also referenced as MK-7240), into its own development portfolio. For retail investors, Prometheus today is effectively an historic position: any remaining exposure runs via Merck’s New York Stock Exchange-listed shares under the ticker MRK rather than via RXDX itself.

From high-growth Nasdaq biotech to Merck’s immunology platform

Before the takeover, Prometheus Biosciences positioned itself as a precision medicine company focused on immune-mediated diseases with a lead program targeting inflammatory bowel disease, which attracted significant attention in the biotech community and on Wall Street as clinical data emerged. The company’s strategy combined large-scale bioinformatics, proprietary diagnostic tools and targeted therapeutics to identify patient subgroups that might benefit most from specific biologic treatments in conditions such as ulcerative colitis and Crohn’s disease. This focus on precision immunology resonated with investors looking for differentiated assets in a crowded autoimmune pipeline landscape, particularly as management pointed to biomarker-driven trial designs and potentially higher response rates compared with legacy anti-TNF or broad immunosuppressive therapies. Prometheus highlighted that its approach aimed to improve both efficacy and safety by narrowing target populations rather than applying a one-size-fits-all drug broadly across heterogeneous patient groups, which was a key selling point in analyst coverage leading up to the Merck bid.

The centerpiece of the story was PRA023, designed to address inflammatory bowel diseases by modulating specific pathways implicated in gut inflammation and fibrosis rather than suppressing the immune system globally. Early-stage trial readouts, which were presented shortly before Merck’s approach, suggested clinically meaningful improvements in endpoints relevant for moderate-to-severe ulcerative colitis and Crohn’s disease, prompting market speculation about partnership deals or a full acquisition by a large pharmaceutical company with established immunology franchises. According to Merck’s own communication at the time of the transaction, the pharma group viewed PRA023 and the broader Prometheus pipeline as complementary to its growing immunology business, which until then had been overshadowed by its flagship oncology product Keytruda. That strategic fit, combined with Merck’s global development and commercialization infrastructure, was cited as a rationale for taking Prometheus off the public markets and moving the programs under a single, better-capitalized umbrella.

From a capital markets perspective, the takeover marked the end of RXDX as a high-beta biotech name trading on the Nasdaq, where it had seen pronounced volatility around clinical catalysts and deal rumors. Shareholders who tendered their stock into the $200.00 per share cash offer realized substantial gains compared with pre-data trading levels, crystallizing value but losing direct exposure to future upside from the pipeline. Any subsequent value creation tied to the former Prometheus programs now accrues to holders of Merck stock, making MRK rather than RXDX the relevant ticker on U.S. exchanges for investors following the story. The absence of an independently traded Prometheus equity also means there are no fresh quarterly results, guidance updates or stand-alone regulatory milestones reported under the RXDX symbol; instead, these elements appear within Merck’s broader financial disclosures and research updates.

On the operational side, Merck has integrated Prometheus’ scientific teams and technology platforms, with the acquired precision immunology capabilities expected to inform pipeline decisions beyond just PRA023. Management commentary around the time of the deal emphasized that Prometheus’ data science and biomarker expertise would be deployed across multiple inflammatory and immune-mediated indications, potentially speeding patient selection and enhancing trial efficiency in Merck’s existing programs. While not broken out separately in current Merck reporting, these assets sit within the company’s research and development structure and contribute to the group’s stated objective of expanding beyond oncology into other high-need therapeutic areas. For former RXDX shareholders who rolled proceeds into Merck or maintained exposure via diversified funds, the performance of those integrated programs is now reflected in MRK’s share price and long-term pipeline narrative rather than in a standalone Prometheus quote.

Legacy listing, but no active RXDX trading or fresh earnings

For U.S. retail investors scanning watchlists and data vendors, a key practical point is that ISIN US7401921006 remains associated with Prometheus Biosciences in many databases even though the stock itself has been delisted following the closing of the Merck transaction. That can lead to confusion when portfolio tools still display RXDX or Prometheus entries without showing real-time prices, bid-ask spreads or daily percentage changes, because there is no active order book on Nasdaq or any other major U.S. exchange for the name. The absence of current trading data is not a system glitch but a direct consequence of the company no longer existing as an independent issuer of publicly traded shares, with all former equity absorbed by Merck for cash consideration at the time of the acquisition. Any apparent price references linked to US7401921006 in third-party tools today typically reflect historical prices or static placeholders, not live quotes accessible for new buy or sell orders.

Along the same lines, there are no stand-alone Prometheus Biosciences quarterly earnings releases or conference calls to track in 2024, 2025 or 2026, because the entity has been folded into Merck’s consolidated financial reporting. Research and development spending related to the former RXDX pipeline, along with any milestone-related accounting, now appears as part of Merck’s broader R&D line items rather than in a separate Prometheus income statement, which means investors cannot isolate Prometheus-specific profitability or cash burn metrics in public filings. Regulatory and clinical milestones for PRA023 and other inherited programs are also communicated under Merck’s name via U.S. Food and Drug Administration announcements, scientific conference presentations and company press releases, so investors following the science must look to MRK-focused news flow instead of an RXDX news page. This integrated disclosure framework is standard practice in large-cap pharmaceutical acquisitions and underscores that the Prometheus story from a capital markets standpoint is now one component of the wider Merck investment case.

For investors who held Prometheus at the time of the deal and accepted the $200.00 per share cash consideration, the legacy ISIN in a portfolio report serves mainly as an accounting record of a closed position rather than as a vehicle for ongoing trading decisions. Tax documentation and historical performance analysis may still reference US7401921006 for capital gains calculations or for benchmarking biotech exposure over time, but new purchases or sales cannot be executed on that identifier in the U.S. equity market. Those who seek renewed exposure to precision immunology initiatives formerly associated with Prometheus must therefore evaluate Merck’s shares and pipeline, or alternative listed biotechs pursuing similar indications, rather than attempt to re-enter RXDX as a standalone equity. In short, the current Prometheus Biosciences listing is a legacy marker more than a live stock, even though the science and assets that once drove RXDX’s valuation continue to advance within a large pharmaceutical framework.

Given this status, there is also no independent analyst rating or price-target consensus published on Prometheus stock in the U.S. market today, as coverage has shifted to Merck, where analysts factor the former Prometheus programs into their broader valuation models for MRK. Sell-side research notes that once focused on RXDX’s upside potential as a small-cap biotech now reference the acquisition as part of Merck’s strategic push into immunology, often highlighting PRA023’s potential market opportunity within the context of competing treatments for ulcerative colitis and Crohn’s disease. Any discussion of valuation, risk-reward or competitive positioning for those assets is framed at the Merck level, where they are weighed against the company’s other growth drivers, patent cliffs and capital allocation priorities. This shift means that tools or websites still listing RXDX among actively rated stocks are relying on outdated snapshots rather than current market practice.

For portfolio construction, the key implication is that the risk profile associated with Prometheus has changed from that of a concentrated, clinical-stage biotech to that of a diversified, large-cap pharmaceutical group through Merck’s NYSE listing. Where RXDX once offered high event-driven volatility around trial readouts, regulatory decisions or licensing deals, exposure through MRK is buffered by the company’s wide range of marketed products and its global revenue base, which can dilute the impact of any single pipeline program on the share price. Investors evaluating whether to hold, increase or reduce exposure to the former Prometheus story now do so primarily within the framework of a broader Merck analysis, incorporating factors such as overall earnings growth, dividend policy, share repurchases and the performance of flagship drugs, rather than treating Prometheus-specific catalysts in isolation. Against this backdrop, the continuing presence of ISIN US7401921006 in some databases should be interpreted as a historical reference rather than a signal of fresh standalone trading opportunities.

For now, Prometheus Biosciences remains relevant mainly as a case study in how promising clinical data and a focused precision-medicine strategy can lead to a premium takeover by a global pharmaceutical company, resulting in delisting and a transition from a small-cap biotech profile to large-cap pharma exposure through the acquirer’s stock. Investors watching the name in portfolio tools or financial news feeds may therefore want to align their information sources: legacy RXDX identifiers capture the past trajectory up to the $200.00 per share buyout, while current developments in the underlying science and commercial prospects are best monitored via Merck’s NYSE-listed shares and associated disclosures.

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.